Alpha-amylase synergist and application thereof

By isolated pyruvate or sodium pyruvate from the fermentation supernatant of Bacillus subtilis X13 as an ɑ-amylase synergist, the problems of indigestion caused by reduced pancreatic amylase secretion and low efficiency in industrial amylase application are solved, and the problem of indigestion caused by reduced pancreatic amylase secretion is achieved. It has the effect of improving pancreatic amylase activity and has safety and economic advantages.

CN118903084APending Publication Date: 2024-11-08ANHUI AGRICULTURAL UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411323782.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Due to the reduction of pancreatic amylase secretion in the elderly and middle-aged and young people, existing pancreatic amylase supplements may cause allergic reactions, and industrial amylase applications are limited by costs and environment, and there is a lack of effective synergists.

Method used

Pyruvate or sodium pyruvate was isolated from the fermentation supernatant of Bacillus subtilis X13, as an ɑ-amylase synergist, and the pancreatic amylase activity is increased through specific concentrations of aqueous solutions, and is used in pharmaceutical, food and industrial applications.

Benefits of technology

It significantly improves the activity of ɑ-amylase, enhances the digestibility of starch, reduces the viscosity of food, and improves the utilization rate of protein and lipids. It has the characteristics of high safety, low cost and good effect, and solves indigestion and The problem of low industrial production efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903084A_ABST
    Figure CN118903084A_ABST
Patent Text Reader

Abstract

The invention provides an alpha-amylase synergist and application thereof, belongs to the technical field of digestion promotion, and provides two alpha-amylase synergists, one alpha-amylase synergist is a pyruvic acid solution with the concentration of 0.532 mol / L to 0.787 mol / L, and the other alpha-amylase synergist is a sodium pyruvate solution with the concentration of 0.011 mol / L to 0.568 mol / L. The invention also provides a chewable tablet, a soft capsule, a capsule, a tablet or an oral liquid for promoting digestion, the chewable tablet, the soft capsule, the capsule or the tablet contains sodium pyruvate powder, and the oral liquid contains pyruvic acid or a sodium pyruvate solution. The alpha-amylase synergist provided by the invention is low in cost, non-toxic and resistant to gastric acid damage, can improve the activity of alpha-amylase such as pancreatic amylase, helps human bodies and animal bodies to digest starch, and also can improve the in-vitro digestibility of the alpha-amylase.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of promoting digestion, and in particular relates to an alpha-amylase synergist and application thereof. Background Art

[0002] With the development of social economy and the significant improvement of medical level, my country is accelerating into an aging society. Due to the decline of physiological functions, the secretion of various digestive enzymes in the elderly is reduced, which seriously affects the digestion and absorption of food. At the same time, with the increase of social work pressure and the accelerated pace of life, many young and middle-aged groups also have many gastrointestinal dysfunction phenomena. According to statistics, the incidence of functional dyspepsia in China is 18-45%, and it is easy to relapse, which seriously affects the quality of life of patients.

[0003] In 1894, Japanese scientists first extracted amylase from Aspergillus oryzae and used it as a drug for treating indigestion. Since then, humans have begun to purposefully produce and apply enzyme preparations. Studies have shown that pancreatic amylase is a key enzyme in the digestive tract to digest and absorb sugar. Studies have found that the activity of serum pancreatic amylase in patients with spleen deficiency syndrome decreases, and the activity of pancreatic amylase decreases with the aggravation of spleen deficiency syndrome. Pancreatic amylase can improve the digestibility of carbohydrates and help reduce food viscosity, thereby improving the nutritional utilization of proteins and lipids.

[0004] Sodium pyruvate is a class of endogenous small molecules. Both sodium pyruvate and pyruvic acid exist naturally in the human body and participate in the metabolism of various tissues and organs throughout the body. Sodium pyruvate is widely used as a buffer, excipient and antioxidant in medicine, diagnostic reagents and medical devices. It can also be used to determine the substrate of lactate dehydrogenase and the activity of glutamic-alanine aminotransferase in liver function tests; it is also a good dietary supplement for fitness and weight loss; it is widely used in food and cosmetics.

[0005] The present invention separates active strain Bacillus subtilis X13 from persimmon enzyme, and its fermentation supernatant can significantly enhance the activity of pancreatic amylase. Through separation, purification, identification and analysis of the fermentation supernatant, the inventor found that pyruvic acid in the fermentation supernatant has the effect of significantly improving the activity of pancreatic amylase. So far, there is no research report on the synergistic effect of pyruvic acid and sodium pyruvate on α-amylase at home and abroad. Summary of the invention

[0006] The present invention first discovered a strain of Bacillus subtilis, which was separated from a high-sugar persimmon enzyme stock solution prepared in the laboratory. The fermentation broth of the strain has the effect of enhancing the activity of pancreatic amylase. The inventor conducted in-depth research on the fermentation broth and found that pyruvic acid or sodium pyruvate solution at a specific concentration has the effect of enhancing the activity of α-amylase, and applied it in medicines and foods, specifically including the following contents.

[0007] A alpha-amylase synergist, wherein the alpha-amylase synergist is a 0.532-0.787 mol / L pyruvic acid solution.

[0008] Another alpha-amylase synergist is a 0.011-0.568 mol / L sodium pyruvate solution.

[0009] Wherein, the solvent of the pyruvic acid solution or the sodium pyruvate solution is water.

[0010] A pyruvic acid aqueous solution with a concentration of 0.532 to 0.787 mol / L can be used to increase the activity of α-amylase.

[0011] A sodium pyruvate aqueous solution with a concentration of 0.011 to 0.568 mol / L is used to increase the activity of α-amylase.

[0012] The invention provides an oral liquid for improving the activity of α-amylase, comprising a pyruvic acid solution or a sodium pyruvate solution.

[0013] The invention provides a chewable tablet, a capsule, a soft capsule and a tablet for improving the activity of α-amylase, comprising sodium pyruvate powder.

[0014] The invention provides an animal feed additive for improving the activity of α-amylase. By adding 1 to 100 g / kg of sodium pyruvate powder to the feed according to the mass ratio, the digestibility of starch in the animal feed can be improved.

[0015] Beneficial Effects

[0016] Starch is the second most abundant green polymer compound in nature. It is not only the most important food crop, but also a safe and highly plastic starch deep processing raw material. These starch deep processing products are mainly produced by amylase degradation starch production technology. So far, amylase has become an important pillar of industrial enzymes, accounting for 50% of the total production value of industrial enzymes, and is widely used in many fields such as food and daily chemicals. Due to the limitations of the working environment and cost, amylases derived from plants and animals are rarely used in actual industrial production, while amylases produced by microorganisms have the advantages of low cost, strong controllability, and environmental friendliness. Therefore, microbial amylases are the main source of industrial amylases. The inventor's experiments show that sodium pyruvate not only has a synergistic effect on pancreatic amylase, but also has a significant synergistic effect on α-amylase derived from Bacillus amyloliquefaciens. If it is applied to industrial amylase, it can improve production efficiency, help reduce costs, and has broad development prospects.

[0017] Sodium pyruvate exists naturally in the human body, participates in the metabolism of three major nutrients, and is a kind of endogenous natural antioxidant. Previous studies have confirmed that it has multiple effects such as anti-oxidation, anti-inflammatory, alkalization, and cell protection. Therefore, sodium pyruvate can be safely applied to the human body, but there is no report about its amylase synergist effect at home and abroad so far. In addition, the current commercially available pancreatic amylase supplements are all derived from animals such as pigs. Due to this source of pancreatic enzyme preparations, allergic reactions to animal proteins in the preparations are occasionally seen. For example, after long-term or high-dose contact, allergic reactions such as asthma, bronchial allergies, and pulmonary allergies may be present. The pancreatic amylase synergist studied by the present invention can improve the pancreatic amylase activity of the human body or animal body itself, and therefore has incomparable advantages in terms of safety.

[0018] The present invention pioneered the discovery that pyruvic acid or sodium pyruvate can improve the activity of α-amylase and improve its starch decomposition ability. The main components of human staple food flour and wheat are starch. The digestibility of starch can be effectively improved by this method. No additional pancreatic amylase is taken, and the problem of indigestion can be solved. The biggest technical problem of taking amylase is that amylase itself is also a protein, and heterologous proteins may cause allergic reactions. Therefore, the effect of taking the synergist is much greater than taking the pancreatic amylase itself. The sodium pyruvate and pyruvic acid provided by the present invention are normal components of body metabolism, present in any human and animal body cells, and are not easily destroyed in gastric acid. After combining with pancreatic amylase, it can significantly improve the effect of pancreatic amylase, with the characteristics of high safety, low cost and good effect. The sodium pyruvate and pyruvic acid aqueous solution provided by the present invention can also improve the activity of α-amylase from microorganisms in vitro, can improve the enzymatic rate of α-amylase in vitro, improve the rate of industrial starch degradation, and improve production efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 The elution curve of pancreatic amylase enhancer in fermentation supernatant by ADS-7 resin was 75% ethanol.

[0020] Figure 2 This is the 190-500nm wavelength spectrum scan of fraction 9 sample liquid.

[0021] Figure 3 This is the 190-500nm wavelength spectrum scanning diagram of sample solution X.

[0022] Figure 4 This is the ethanol concentration gradient elution curve of the pancreatic amylase enhancer in sample solution X by ADS-7 resin.

[0023] Figure 5 This is the 190-500nm wavelength spectrum scan of fraction 38 sample liquid. DETAILED DESCRIPTION

[0024] The present invention is described in detail below with reference to examples. All methods and techniques are conventional methods and techniques.

[0025] Bacillus subtilis X13 is a strain isolated from persimmon enzyme by our research group and is deposited in China Center for Type Culture Collection with the accession number: CCTCC M 2023165.

[0026] Pancreatic amylase (45 U / mg), Shanghai MacLean Biochemical Technology Co., Ltd.; methanol (analytical grade), Chengdu Cologne Chemical Co., Ltd.; ethyl acetate (analytical grade), Shanghai Haohong Biomedical Technology Co., Ltd.; macroporous resin ADS-7, D101, Anhui Samsung Resin Co., Ltd.; pyruvic acid (purity 98%), Shanghai Yien Chemical Technology Co., Ltd.; sodium pyruvate (purity 99%), Tianjin Zhonglian Chemical Reagent Co., Ltd.; α-amylase from Bacillus amyloliquefaciens (250 U / g), Shanghai Aladdin Biochemical Technology Co., Ltd.

[0027] The method for determining the amylase activity in the present invention is as follows.

[0028] (1) Iodine solution: Accurately weigh 1g potassium iodide and 0.4g iodine, dissolve them completely with a small amount of distilled water, make up to 100mL, shake well and store in a brown bottle. Before the experiment, take 3mL of the solution, dilute it to 100mL with distilled water, and store in a brown bottle for later use.

[0029] (2) Disodium hydrogen phosphate-citric acid buffer solution (pH=6.6): Prepare 0.2 mol / L disodium hydrogen phosphate solution and 0.1 mol / L citric acid solution respectively, take 14.55 mL of the disodium hydrogen phosphate solution and 5.45 mL of the citric acid solution and mix them thoroughly to obtain a disodium hydrogen phosphate-citric acid buffer solution with a pH of 6.6.

[0030] (3) 0.01 g / mL starch solution: Weigh 1 g of soluble starch and add a certain amount of sodium hydrogen phosphate-citric acid buffer solution (pH = 6.6) to dissolve by heating until transparent. After cooling, add the buffer solution to make up to 100 mL and store at room temperature.

[0031] (4) Reaction termination solution: Weigh 1 g of copper chloride and dilute to 10 mL with distilled water. Measure 9 mL of 37% hydrochloric acid and dilute to 90 mL with distilled water. Mix the two to obtain the termination solution.

[0032] (5) Pancreatic amylase solution: Weigh 0.001 g of pancreatic amylase into a centrifuge tube, add 60 mL of disodium hydrogen phosphate-citric acid buffer (pH = 6.6), shake well to obtain a 0.75 U / mL pancreatic amylase solution, and then dilute it 2 times with disodium hydrogen phosphate-citric acid buffer (pH = 6.6) to obtain a 0.375 U / mL pancreatic amylase solution.

[0033] (6) Test solution: Take 2 mL of 0.75 U / mL pancreatic amylase solution and 2 mL of fermentation supernatant, mix and shake well, and preheat in a 37°C water bath for 5 min to obtain the test solution.

[0034] (7) Determination of pancreatic amylase activity.

[0035] ① Blank tube: Take 5 mL of disodium hydrogen phosphate-citric acid buffer (pH=6.6) and add it to a test tube, place it in a 37°C water bath for 10 minutes, and then add 1 mL of disodium hydrogen phosphate-citric acid buffer (pH=6.6) preheated to 37°C and stop solution. Shake well and cool to room temperature, take 0.2 mL into a test tube, and then add 7 mL of iodine solution.

[0036] ② Add 1mL of the sample solution to be tested into the test tube as the sample tube, add 1mL of sodium dihydrogen phosphate-citric acid buffer (pH=6.6) into the test tube as the standard tube, add 1mL of 0.375U / mL amylase solution into the test tube as the pure enzyme tube, place all the test tubes in a 37℃ water bath for 2min, then add 5mL of 0.01g / mL starch solution preheated in a 37℃ water bath in sequence, and mix immediately. After reacting at 37℃ for 10min, immediately add 1mL of stop solution. Shake well and cool to room temperature, take 0.2mL into the test tubes respectively, then add 7mL of iodine solution respectively, shake well, and measure the absorbance at a wavelength of 580nm using a spectrophotometer after calibrating with a blank tube.

[0037] The calculation formula of pancreatic amylase activity is as follows: incubate at 37°C for 10 minutes, and 1 unit (U) of pancreatic amylase activity is defined as the hydrolysis of 1 mg of soluble starch substrate per minute.

[0038] The amount of starch in the sample tube, standard tube and pure enzyme tube is 5mL 1% starch, that is, 50mg. The amount of starch degradation in the sample tube is (50-m x )mg, the calculation formula of the enzyme activity in the sample tube is:

[0039]

[0040] Where: m x - Starch amount in the sample tube (mg); A X -Absorbance of sample tube; m s - Starch amount in the standard tube (mg); AS -Absorbance of standard tubes.

[0041] (8) The calculation formula for determining the activity of pancreatic amylase enhancer is as follows.

[0042] Pancreatic amylase enhancer activity (fold / mL) = sample tube enzyme activity / pure enzyme tube enzyme activity - 1

[0043] Example 1

[0044] The applicant found that the high-sugar persimmon enzyme stock solution has a significant function of aiding digestion, so the effective strains therein were studied. The results showed that Bacillus subtilis X13 in one of the persimmon enzyme stock solutions has the function of a high-yield amylase activator.

[0045] The methods for extraction, separation, purification and identification of the active ingredients of α-amylase enhancer in the fermentation supernatant of Bacillus subtilis X13 are as follows.

[0046] (1) Methanol removal: The fermentation supernatant was concentrated 10 times by rotary evaporation (20 r / min, 40°C), and the same volume of methanol was added to the concentrate. After shaking, the mixture was placed in a 4°C refrigerator. After standing for 1.5 h, the mixture was centrifuged (10,000 r / min, 10 min, 4°C). After centrifugation, the supernatant was taken and rotary evaporated (20 r / min, 40°C) to remove methanol.

[0047] (2) Ethyl acetate extraction: Weigh the same volume of ethyl acetate as the concentrate after methanol treatment and add it to a separatory funnel. Shake it thoroughly. After standing for stratification, separate the lower layer of concentrate and the upper layer of organic phase and place them in a beaker. Repeat the extraction of the concentrate 5 times, combine the organic phases and perform rotary evaporation (20r / min, 40°C). After removing the organic phase, add pure water to re-dissolve.

[0048] (3) Weigh a certain amount of macroporous resin ADS-7 and soak it in anhydrous ethanol for at least 24 hours, wash it repeatedly with ultrapure water until it does not contain ethanol, and set aside. Weigh 45g of the pretreated macroporous resin, add 200mL of the sample solution extracted with ethyl acetate (the concentration is twice the concentration of the original solution), stir evenly and put it in an oscillating incubator (120r / min, 20℃, 2h) to allow the enzyme enhancer to be fully adsorbed on the macroporous resin. After the adsorption is completed, the macroporous resin is loaded on the column, and the column loading volume is 1 / 2 of the volume of the chromatography column (ф30mm×300mm). During the process, the chromatography column is constantly tapped with an ear bulb. After the column loading is completed, it is eluted with 400mL of 75% ethanol solution. After 250mL of elution is completed, a fraction is collected every 10mL. The obtained fraction is subjected to rotary evaporation (20r / min, 40℃), and then re-dissolved in pure water.

[0049] (4) Select macroporous resin D101, and pretreat in the same manner as above. After pretreating, perform secondary adsorption on the active fraction 9 sample solution from the first column chromatography, i.e., weigh 30 g of pretreating macroporous resin D101, add 50 mL of fraction 9 sample solution diluted 10 times, stir evenly, and place in a shaking incubator (120 r / min, 20°C, 2 h). Then, add sample solution X after secondary adsorption to 30 g of pretreating macroporous resin ADS-7, stir evenly, and place in a shaking incubator (120 r / min, 20°C, 2 h). After adsorption, load macroporous resin ADS-7 onto the column, and the loading amount is 2 / 3 of the volume of the chromatography column (ф20 mm×250 mm). The eluents were ethanol solutions with four concentration gradients of 25%, 50%, 75%, and 90%. The volume of each eluent was 150 mL. One fraction was collected every 10 mL, and a total of 60 fractions were obtained. The obtained fractions were subjected to rotary evaporation (20 r / min, 40°C), and then re-dissolved in pure water.

[0050] (1) Metabolite extraction: Pipette 50 μL of sample fraction 4 prepared in 1.2.2.2 into an EP tube, add 200 μL of extracting solution (methanol:acetonitrile = 1:1 (V / V)), the extracting solution contains an isotope-labeled internal standard; vortex mix for 30 seconds, sonicate for 10 minutes (ice water bath); let stand at -40°C for 1 hour; centrifuge the sample at 4°C, 12,000 rpm for 15 minutes; take the supernatant into the injection bottle for detection;

[0051] (2) On-machine detection: Vanquish (Thermo Fisher Scientific) ultra-high performance liquid chromatograph was used to separate the target compounds by chromatography on a Waters ACQUITY UPLC BEH Amide (2.1 mm × 50 mm, 1.7 μm) liquid chromatography column. Phase A of the liquid chromatography was an aqueous phase containing 25 mmol / L ammonium acetate and 25 mmol / L ammonia water, and phase B was acetonitrile. Sample plate temperature: 4 °C, injection volume: 2 μL. The Orbitrap Exploris 120 mass spectrometer was able to perform primary and secondary mass spectrometry data acquisition under the control of the control software (Xcalibur, version: 4.4, Thermo). The detailed parameters are as follows: Sheath gas flow rate: 50Arb, Aux gas flow rate: 15Arb, Capillary temperature: 320℃, Full ms resolution: 60000, MS / MS resolution: 15000, Collision energy: SNCE 20 / 30 / 40, Spray Voltage: 3.8kV (positive) or -3.4kV (negative).

[0052] (3) Data processing: The raw data were converted into mzXML format using ProteoWizard software, and metabolite identification was performed using a collaboratively written R package, using the BiotreeDB (V3.0)7 database, and then visual analysis was performed using an independently written R package.

[0053] The fermentation supernatant of Bacillus subtilis X13 was purified by methanol, extracted with ethyl acetate, and eluted with 75% ethanol on a macroporous resin ADS-7 column to collect fractions 9( Figure 1 ), fraction 9 was subjected to secondary adsorption by macroporous resin D101 column material to obtain sample solution X, and then sample solution X was subjected to macroporous resin ADS-7 column chromatography with ethanol concentration gradient elution. The elution curve showed that the peaks could basically achieve baseline separation, and the peak with the highest activity, i.e., fraction 38 ( Figure 4 ).Depend on Figure 2 , Figure 3 and Figure 5It can be seen that after separation and purification, the impurity peaks of the fermentation supernatant of Bacillus subtilis X13 were significantly reduced, and the peak shape of the target absorption peak was more symmetrical, indicating that the purification effect was good. The 38 samples of the fraction were sent for liquid-to-mass analysis, and a total of 380 level 1 organic substances were identified, that is, the metabolites in the samples matched the MS1, MS2 and RT of the standard. Based on the chemical characteristics of the pancreatic amylase enhancer produced by strain X13, that is, medium to upper polarity and an absorption peak at 320nm in the ultraviolet spectrum, the inventors screened pyruvic acid as a possible target for the following verification experiment.

[0054] Example 2

[0055] This example verifies the synergistic effect of pyruvate or sodium pyruvate on α-amylase by measuring the effects of different concentrations of pyruvate, different pH values, different concentrations of sodium pyruvate, pancreatic amylase concentrations and contact time on amylase synergism. The specific method is as follows:

[0056] ① Effect of pyruvate concentration on the synergistic effect of pancreatic amylase: Pyruvate solutions with a pH of 6.0 and a concentration of 0.352, 0.568, 0.628, 0.708, and 0.787 mol / L were prepared to replace the fermentation supernatant to prepare the test solution.

[0057] ② Effect of pH value on the synergistic effect of pyruvate solution on pancreatic amylase: Preparation of disodium hydrogen phosphate-citric acid buffer solution (pH = 6.2): ​​Prepare 0.2 mol / L (27.22 g / L) disodium hydrogen phosphate solution and 0.1 mol / L (19.2 g / L) citric acid solution respectively, take 13.22 mL disodium hydrogen phosphate solution and 6.78 mL citric acid solution and mix them thoroughly to obtain a disodium hydrogen phosphate-citric acid buffer solution with a pH of 6.2. Prepare 0.708 mol / L pyruvate solution with pH values ​​of 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, and 7.0 respectively to replace the fermentation supernatant to prepare the test solution.

[0058] ③ Effect of the concentration of sodium pyruvate solution (pH 6.2) on the synergistic effect of pancreatic amylase: Sodium pyruvate solutions with a pH of 6.2 and concentrations of 0.011, 0.022, 0.044, 0.088, 0.132, 0.176, 0.352, and 0.568 mol / L were prepared to replace the fermentation supernatant to prepare the test solution.

[0059] ④ Effect of contact time of sodium pyruvate and pancreatic amylase on synergistic effect: Take 2mL of 0.75U / mL pancreatic amylase solution and 2mL of 0.022mol / L sodium pyruvate solution, mix and shake well, and preheat in a 37℃ water bath for 3, 4, 5, 6, and 7min respectively.

[0060] The experimental results showed that pyruvic acid solution (pH 6.0) enhanced the activity of pancreatic amylase in a dose-dependent manner, but its synergistic activity would decrease if the concentration was too high. As shown in Table 1, 0.708 mol / L pyruvic acid solution had the strongest synergistic activity. Therefore, this concentration was used as the optimal pyruvic acid concentration in subsequent experiments.

[0061] Table 1 Effects of different concentrations of pyruvic acid solution (pH 6.0) on the synergistic effect of pancreatic amylase

[0062]

[0063] When the activity of pancreatic amylase is measured, the pH value of the buffer is 6.6, while the pH value of pyruvic acid is lower, so the pH value of the pyruvic acid solution may affect its synergistic activity. This experiment determined the effect of pH on the synergistic effect of pancreatic amylase with pyruvic acid solution (0.708 mol / L). The experiment showed that there was no significant difference in the enzyme activity when the pH value of disodium hydrogen phosphate-citric acid buffer solution was adjusted to 6.2 and 6.6, indicating that the pH value had little effect on the determination of pancreatic amylase activity, while the synergist activity of pyruvic acid solution (0.708 mol / L) at pH 6.2 was 1.27 times that at pH 6.6 (Table 2), indicating that the pH value significantly affects the synergistic activity of pyruvic acid on pancreatic amylase. Therefore, as a synergist, the optimal pH value of 0.708 mol / L pyruvic acid solution is 6.2. NaOH may produce a certain amount of sodium pyruvate in the process of adjusting the pH value of pyruvic acid solution, so the subsequent experiment should verify the synergistic effect of sodium pyruvate.

[0064] Table 2 Effect of pH value on the synergistic effect of pancreatic amylase in pyruvic acid solution (0.708 mol / L)

[0065]

[0066] The experimental results show (Table 3) that only the sodium pyruvate solution with a lower concentration has a higher synergistic activity compared to the pyruvic acid solution, indicating that pancreatic amylase is more sensitive to the synergistic effect of sodium pyruvate. In addition, the acidity of pyruvic acid is much higher than that of sodium pyruvate, and a large amount of alkali solution needs to be added before use to adjust the pH value, which limits the practical application of pyruvic acid as a pancreatic amylase synergist. Therefore, subsequent experiments will study sodium pyruvate as a pancreatic amylase synergist.

[0067] Table 3 Effect of sodium pyruvate solution (pH 6.2) concentration on its pancreatic amylase synergistic effect

[0068]

[0069] Since the activity of enzyme synergists may also be affected by enzyme concentration, that is, when the synergist improves the catalytic efficiency of pancreatic amylase, but the enzyme concentration is not enough to support the high-efficiency synergistic effect, the synergistic effect of the synergist may be reduced. Therefore, this experiment studies the effect of increasing the concentration of pancreatic amylase on the synergistic effect of sodium pyruvate. The results show (Table 4) that when the concentration of pancreatic amylase is increased by 1 times, the synergistic activity of 0.022mol / L sodium pyruvate is 1.20 times that of the control group (unchanged enzyme concentration), indicating that increasing the concentration of pancreatic amylase can enhance the synergistic effect of sodium pyruvate. Table 3 shows that when the concentration of sodium pyruvate solution is higher than 0.022mol / L, the synergistic activity begins to decline. This experiment shows that when the enzyme concentration increases, the synergistic activity of sodium pyruvate solution begins to decline when the concentration is higher than 0.044mol / L. Therefore, when eating, the pancreas will secrete pancreatic amylase, and the synergistic effect of sodium pyruvate will also increase accordingly, and the phenomenon of the synergistic effect of higher concentration sodium pyruvate will not occur at the same time.

[0070] Table 4 Effect of doubling the concentration of pancreatic amylase on the synergistic effect of sodium pyruvate

[0071]

[0072] When sodium pyruvate is used as a pancreatic amylase synergist in actual application, whether the contact time with pancreatic amylase in the intestine will affect its synergistic effect, the experimental results (Table 5) show that the pancreatic amylase synergistic activity of 0.022 mol / L sodium pyruvate is highest when it is in contact with pancreatic amylase for 5 minutes, but its synergistic activity is higher under the conditions of long or short contact time, indicating that its onset time is faster, and its synergistic activity will not be reduced too much even if it acts on pancreatic amylase for a long time, and its practical application performance is stronger.

[0073] Table 5 Effect of contact time of sodium pyruvate and pancreatic amylase on synergistic effect

[0074]

[0075] Example 3

[0076] In this example, the synergistic effect of sodium pyruvate on α-amylase from Bacillus amyloliquefaciens was studied by preparing α-amylase (derived from Bacillus amyloliquefaciens) solutions with concentrations of 0.75 U / mL and 0.375 U / mL to replace pancreatic amylase. Other methods were the same as in Example 2.

[0077] Pancreatic amylase is an animal-derived α-amylase. In order to explore whether sodium pyruvate has a similar synergistic effect on α-amylases from other sources, this experiment determined the synergistic activity of sodium pyruvate on α-amylase from Bacillus amyloliquefaciens. As shown in Table 6, different concentrations of sodium pyruvate solutions (pH 6.2) have obvious synergistic activity on α-amylase from Bacillus amyloliquefaciens.

[0078] Table 6 Effect of different concentrations of sodium pyruvate solution on the synergistic effect of α-amylase from Bacillus amyloliquefaciens

[0079]

[0080] Example 4

[0081] The mouse experiment preliminarily explored whether sodium pyruvate solution could increase the activity of pancreatic amylase. The mice were gavaged with a maximum gavage volume of 0.2 mL per 10 g body weight. The control group was gavaged with normal saline, and each experimental group was gavaged with 0.02 g, 0.1 g, and 0.2 g of sodium pyruvate solution, respectively. The results showed that the activity of pancreatic amylase increased by 0.13 to 0.42 times.

[0082] Pyruvate can be found in the general diet. The human body naturally ingests 0.1 to 2 g per day. The content of pyruvate is low in most foods, but it is very high in some vegetables and fruits (such as 450 mg in red apples). Other foods such as dark beer (340 g) contain 80 mg and red wine (1700 g) contain 75 mg. Therefore, the safety of pyruvate is beyond doubt. It can be seen that sodium pyruvate solution can be safely prepared into oral solution, chewable tablets or capsules. As long as the final concentration of sodium pyruvate solution combined with pancreatic amylase is 0.011 to 0.568 mol / L, the effect of increasing the activity of pancreatic amylase can be achieved.

[0083] Example 5

[0084] A drug for promoting starch digestion in human body is in the form of soft capsule or capsule. The soft capsule or capsule contains 5-100 mg of sodium pyruvate. The effective component is a sodium pyruvate aqueous solution formed by sodium pyruvate meeting water. Finally, a sodium pyruvate solution of 0.011-0.568 mol / L is formed in human body.

[0085] This embodiment also provides an oral liquid for promoting starch digestion in the human body. The oral liquid contains pyruvic acid, and the concentration of the pyruvic acid is 0.532-0.787 mol / L.

[0086] After taking the above-mentioned drugs and oral liquids that promote starch digestion in the human body, sodium pyruvate or pyruvic acid reacts with pancreatic amylase to increase the activity of pancreatic amylase, which can help quickly digest and decompose starchy foods, thereby helping digestion and improving digestibility.

[0087] Example 6

[0088] A feed additive for promoting animal digestion, wherein 1 to 100 g / kg of sodium pyruvate is added to the feed, and the amount of addition is determined according to the size and nutritional status of the animal. After addition, the activity of pancreatic amylase in the animal can be increased, thereby helping the animal digest and promoting growth. Experiments on mice show that after adding 0.01 g, 0.05 g, 0.1 g, 0.5 g and 1 g of sodium pyruvate to 10 g of feed, the activity of pancreatic amylase is increased by 0.18 to 0.46 times compared with that without addition.

Claims

1. α-amylase synergist, characterized in that: The α-amylase synergist is a 0.532-0.787 mol / L pyruvic acid solution. 2.α-amylase synergist, characterized in that: The α-amylase synergist is a 0.011-0.568 mol / L sodium pyruvate solution.

3. The α-amylase synergist according to claim 1 or 2, characterized in that: The solvent of the pyruvic acid solution or the sodium pyruvate solution is water.

4. The α-amylase synergist according to claim 1 or 2, characterized in that: The α-amylase is pancreatic amylase or Bacillus amyloliquefaciens amylase.

5. An application of the pyruvic acid aqueous solution according to claim 3, wherein the concentration of the pyruvic acid aqueous solution is 0.532-0.787 mol / L, characterized in that: The sodium pyruvate aqueous solution is used to improve the activity of α-amylase.

6. Use of the sodium pyruvate aqueous solution according to claim 3, wherein the concentration of the sodium pyruvate aqueous solution is 0.011-0.568 mol / L, characterized in that: The sodium pyruvate aqueous solution is used to improve the activity of α-amylase.

7. A chewable tablet, capsule, soft capsule and tablet for improving the activity of pancreatic amylase, characterized in that: The chewable tablets, capsules, soft capsules and tablets for improving pancreatic amylase activity include sodium pyruvate powder.

8. An oral liquid for improving pancreatic amylase activity, characterized in that: The oral solution for improving the activity of pancreatic amylase is a pyruvic acid aqueous solution with a final concentration of 0.532-0.787 mol / L or a sodium pyruvate aqueous solution with a final concentration of 0.011-0.568 mol / L.

9. A feed additive for promoting animal digestion, characterized in that: The feed additive for promoting animal digestion is sodium pyruvate. Adding 1-100 g / kg of sodium pyruvate powder to the feed according to the mass ratio can improve the digestibility of starch in the animal feed.

Citation Information

Patent Citations

  • Magnetic macroporous polymeric hybrid scaffolds for immobilizing bionanocatalysts

    CN109068659A

  • Fish feed attractant containing glycosyl isopropyl sulfide

    CN109393207A

  • Recombinant expression vector for producing L-tyrosine, recombinant engineering bacteria and construction method of recombinant engineering bacteria

    CN117106813A

  • Palatinose for enhancing dietary supplement and pharmaceutical delivery

    US20060153899A1